Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Alkermes plc (NASDAQ: ALKS) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Alkermes plc (NASDAQ: ALKS) concerning whether a series of statements by Alkermes plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 6, 2017, U.S. Senator Kamala Harris revealed that she is opening an investigation into the Alkermes sales practices for its opioid-addiction treatment Vivitrol. The senator stated that the Company "aggressively marketed" its medication, persuading judges and prison officials to use it rather than more proven addiction treatments and spent hundreds of thousands of dollars lobbying policymakers.

On this news, NASDAQ: ALKS fell sharply during intraday trading on November 7, 2017.

Based in Dublin, Ireland, and founded in 1987 Alkermes plc researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide.

If you purchased shares of Alkermes plc (NASDAQ: ALKS) on or before November 6, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185